Medical Affairs and Scientific Communications Forum

Recent changes to the reimbursement landscape have elevated the importance of health economics and outcomes research (HEOR) within the pharmaceutical industry. Ensuring that a new medicine or device provides the health care system with “value” is the focus of the science of HEOR. As a result of new demands from payers and Population-Based Decision Makers (PBDMs), market access considerations are now seen as integral to drug development from its earliest stages and throughout its life cycle. During development, companies collect important information to help define the clinical value of a new medicine - from clinical metrics to patient reported outcomes and preference studies. Compiling this information into a cogent dossier to inform a formulary decision or health technology assessment is a specialized form of communication that benefits from an understanding of clinical science, health economics, and systems policies. This session will introduce key concepts in HEOR, discuss current regulatory landscape, and provide insights and tools to prepare value dossiers for submission to US health plans and to HTA-based national health programs. Best practices in presenting HEOR communications and preparing pharmacoeconomic publications will be discussed.